Literature DB >> 25283996

Differences in EQ-5D-3L health state valuations among patients with musculoskeletal diseases, health care professionals and healthy volunteers.

Anja Schwalm1, You-Shan Feng2, Jörn Moock3, Thomas Kohlmann2.   

Abstract

BACKGROUND: Results from existing studies indicate that different respondent groups' health state valuations in cost-utility analyses are not equivalent.
OBJECTIVES: The objectives in our study were to analyse differences in health state valuations among three respondent groups in the context of medical rehabilitation in Germany.
METHODS: Using the time trade-off (TTO) technique, valuations of EQ-5D-3L health states were obtained from patients with musculoskeletal diseases, healthy volunteers and health care professionals. We used linear mixed models to predict TTO utilities and specified and tested interaction effects.
RESULTS: We identified statistically significant (p < 0.05) differences among the three groups in six out of 42 health states. On average, patients' TTO values were somewhat higher compared with other respondent groups. Most of these differences occurred in severe health states. Mean differences and mean absolute differences were 0.02 and 0.14 for patients vs healthy volunteers and 0.06 and 0.14 for patients vs health care professionals. Furthermore, significant effects among respondents were observed for seven of the 22 possible interactions describing differences between respondent groups. Coefficients associated with significant interaction effects ranged from 0.08 to 0.18 (absolute values).
CONCLUSION: The results of our study suggest that TTO valuations of health states differ depending on the specific respondent group from which valuations are obtained. On average, these differences were small. However, researchers and decision makers should remain aware of these differences when interpreting incremental cost-utility assessments.

Entities:  

Keywords:  Cost effectiveness; Health status; Patient preference; Quality of life; Quality-adjusted life years

Mesh:

Year:  2014        PMID: 25283996     DOI: 10.1007/s10198-014-0636-y

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  29 in total

1.  To what extent can we explain time trade-off values from other information about respondents?

Authors:  Paul Dolan; Jennifer Roberts
Journal:  Soc Sci Med       Date:  2002-03       Impact factor: 4.634

2.  Understanding differences between self-ratings and population ratings for health in the EuroQOL.

Authors:  Ralph P Insinga; Dennis G Fryback
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

3.  The gap effect: discontinuities of preferences around dead.

Authors:  Peep F M Stalmeier; Jan J V Busschbach; Leida M Lamers; Paul F M Krabbe
Journal:  Health Econ       Date:  2005-07       Impact factor: 3.046

4.  QALYs: some challenges.

Authors:  Erik Nord; Norman Daniels; Mark Kamlet
Journal:  Value Health       Date:  2009-03       Impact factor: 5.725

5.  Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses.

Authors:  M E Suarez-Almazor; B Conner-Spady
Journal:  J Rheumatol       Date:  2001-03       Impact factor: 4.666

6.  Associations between health status and utilities implications for policy.

Authors:  L A Lenert; J R Treadwell; C E Schwartz
Journal:  Med Care       Date:  1999-05       Impact factor: 2.983

7.  Whose preferences count?

Authors:  P Dolan
Journal:  Med Decis Making       Date:  1999 Oct-Dec       Impact factor: 2.583

8.  Valuing the health state 'tinnitus': differences between patients and the general public.

Authors:  Michael Happich; Thomas von Lengerke
Journal:  Hear Res       Date:  2005-09       Impact factor: 3.208

9.  Health state valuations of patients and the general public analytically compared: a meta-analytical comparison of patient and population health state utilities.

Authors:  Yvette Peeters; Anne M Stiggelbout
Journal:  Value Health       Date:  2009-09-10       Impact factor: 5.725

10.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.